Complete Story


Moderna Reports Positive Data on Early-stage COVID-19 Vaccine Trial

Its stock shares surge

Moderna’s closely watched early-stage human trial for a coronavirus (COVID-19) vaccine produced COVID-19 antibodies in all 45 participants, the biotech company announced Monday, sending the company’s shares surging more than 17 percent.

Each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group. Participants received two doses of the potential vaccine via intramuscular injection in the upper arm approximately 28 days apart.

At day 43, or two weeks following the second dose, levels of binding antibodies in the 25 microgram group were at the levels generally seen in blood samples from people who recovered from the disease, the Cambridge, Massachusetts-based company said. Those in the 100 microgram had antibodies that “significantly exceeded levels in recovered patients. Data on a second dose was not available for the 250 microgram group, the company said.

Please select this link to read the complete article from CNBC.

Printer-Friendly Version